Thrombotic microangiopathies: multimers, metalloprotease, and beyond.
The pathophysiology of various types of thrombotic microangiopathies is coming progressively into focus. Therapeutic advances are likely to follow at a quickening pace. This discussion focuses on thrombotic thrombocytopenic purpura (TTP), the hemolytic-uremic syndrome (HUS), thrombotic microangiopathies associated with transplantation-immunosuppression or anti-angiogenesis therapy, and the preeclampsia/hemolysis-elevated liver enzymes and low platelets syndrome (HELLP).
Moake
Joel
J
Rice University, Houston, Texas, USA. jmoake@rice.edu
D051722:ADAM Proteins / Q000378:metabolism; D000071120:ADAMTS13 Protein; D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D045726:Metalloproteases / Q000378:metabolism*; D008954:Models, Biological; D010973:Platelet Adhesiveness; D017434:Protein Structure, Tertiary; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis / Q000235:genetics; D057049:Thrombotic Microangiopathies / Q000175:diagnosis* / Q000201:enzymology* / Q000503:physiopathology; D014841:von Willebrand Factor / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D014841:von Willebrand Factor; D045726:Metalloproteases; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human